Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Nexstim

14,20 EUR

+0,35 %

5.596 følger denne virksomhed

NXTMH

First North Finland

Medical Equipment & Services

Health Care

Oversigt
Finansielt overblik og estimater
Investorkonsensus
Sammenligne
+0,35 %
-5,65 %
+11,37 %
+40,59 %
+79,75 %
+108,82 %
+225,69 %
+175,63 %
-97,66 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Læs mere
Markedsværdi
102,43 mio. EUR
Aktieomsætning
43,18 t EUR
P/E (adj.) (25e)
25,13
EV/EBIT (adj.) (25e)
24,44
P/B (25e)
12,99
EV/S (25e)
6,63
Udbytteafkast, % (25e)
-
Dækning
Anbefaling
Reducer
Kursmål
12.50 EUR
Opdateret
18.08.2025
Disclaimer
Antti Siltanen
Antti Siltanen

Analytiker

Seneste analyse

Seneste analyse

Udgivelse: 18.08.2025

Seneste omfattende analyse

Udgivelse: 26.06.2025

Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Risiko
Forretningsrisiko
Værdiansættelsesrisiko
Lav
Høj
Alle
Analyse
Selskabsmeddelelser
ViserAlle indholdstyper
Life Science Companies as Investments | Life Science Night Dec. 9, 202514:40
Videoi går

Life Science Companies as Investments | Life Science Night Dec. 9, 2025

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia TechnologiesBioretecBiohitFaron PharmaceuticalsModulightNexstimOrionBittiumDetection TechnologyOptomedRevenio GroupNightingale HealthHerantis PharmaNanoform Finland
Pressemeddelelse3.12.2025, 07.59

BioStock: Nexstim: from Helsinki to a global brain revolution

Nexstim
Pressemeddelelse20.11.2025, 07.00

Nexstim Receives NBS 6 System Order from New Research Customer

Nexstim

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse19.11.2025, 07.28

BioStock: Video from Nexstim's presentation at BioStock Life Science Summit 2025

Nexstim
Pressemeddelelse27.10.2025, 07.00

Hospital in Finland Orders Nexstim NBS 6 System

Nexstim
Nexstim Q3'25: Steady progress during the fall
Analytikerkommentar23.10.2025, 07.01 af
Antti Siltanen

Nexstim Q3'25: Steady progress during the fall

Nexstim published its Q3’25 business update on Wednesday. The company reported that it delivered 16 systems during Q1-Q3.

Nexstim
Pressemeddelelse22.10.2025, 06.00

Nexstim Plc Business Update Q3 2025

Nexstim
Pressemeddelelse14.10.2025, 06.00

Private Medical Center in Finland Orders Nexstim NBS 6 System

Nexstim
Nexstim received diagnostic approval also in the US
Analytikerkommentar13.10.2025, 05.57 af
Antti Siltanen

Nexstim received diagnostic approval also in the US

Nexstim announced on Friday that it had received diagnostic approval for its NBS 6 system in the United States. The news follows the recent similar MDR certification in Europe.

Nexstim
Pressemeddelelse10.10.2025, 13.00

Nexstim releases the NBS 6 for diagnostic use in the United States

Nexstim
NBS 6 diagnostic system received MDR certification in the EU as expected
Analytikerkommentar10.10.2025, 06.41 af
Antti Siltanen

NBS 6 diagnostic system received MDR certification in the EU as expected

On Thursday, Nexstim announced it had received MDR (Medical Device Regulation) certification for its NBS 6 diagnostic system. The approval enables the sale of NBS 6 in Europe with both therapeutic and diagnostic features.

Nexstim
Pressemeddelelse9.10.2025, 11.00

Nexstim Receives NBS 6 System Order from US Customer

Nexstim
Selskabsmeddelelse9.10.2025, 08.58

Correction: Insider information: Nexstim’s NBS 6 diagnostics system receives MDR certification in the EU

Nexstim
Selskabsmeddelelse9.10.2025, 08.25

Nexstim’s NBS 6 diagnostics system receives MDR certification in the EU

Nexstim
Selskabsmeddelelse8.10.2025, 06.00

Nexstim Plc: Share subscriptions based on stock options 2020 and 2023

Nexstim
Pressemeddelelse7.10.2025, 06.00

Nexstim Receives System Order from US Clinic

Nexstim
Pressemeddelelse23.9.2025, 06.15

Nexstim Receives NBS 5+ System Order from Pediatric Hospital in United States

Nexstim
Regulation of medical devices and diagnostics in Europe
Analytikerkommentar19.9.2025, 05.18 af
Antti Siltanen

Regulation of medical devices and diagnostics in Europe

The EU is the world's second largest market for medical devices after the United States. In this article, we will go through the basics of EU regulation from an investor's perspective.

BioretecAiforia TechnologiesNexstimBiohitOptomedRevenio GroupModulightDetection TechnologyNightingale HealthBittium
Pressemeddelelse16.9.2025, 06.00

Nexstim Receives NBS 5+ System Order from Therapy Customer in United States

Nexstim
Classification of medical devices and regulatory processes in the United States
Analytikerkommentar8.9.2025, 09.56 af
Antti Siltanen

Classification of medical devices and regulatory processes in the United States

We continue our series of articles focusing on Life Science investing, the first four parts of which focused on drug development. Subsequent articles will cover medical devices.

BioretecNexstimOptomedRevenio GroupModulightBittiumDetection Technology
Forumopdateringer
Det ser ud til at gå til stregen igen, men det gjorde det jo også sidste år:
4.12.2025, 07.37
af Kyhnykeisari
23
Biostock – 3 Dec 25 Nexstim: from Helsinki to a global brain revolution Finnish Nexstim's vision is to offer personalized diagnostics and therapy for serious brain diseases and disorders. To achieve this, it has developed a non-invasive technology for brain stimulation. The treatment...
3.12.2025, 09.10
af Kyhnykeisari
20
canhealth.com CABHI awards $2.8M to advance the brain economy | Canadian Healthcare Technology TORONTO - The Centre for Aging + Brain Health Innovation (CABHI), powered by Baycrest, has allocated $2.8 million CAD in funding to eight early- to mid-stage researchers and companies through...
3.12.2025, 22.19
af Jatast
18
Google-søgninger inden for emnet Transcranial magnetic stimulation er næsten fordoblet i Q3/2025 sammenlignet med Q3/2024. Disse er altså ikke reelle søgemængder, men indekserede og samlede på kvartalsniveau. Originaldataen findes her: https://trends.google.com/trends/explore?date...
8.12.2025, 07.34
af Kyhnykeisari
16
Jeg lever nu stadig i den tro, at de også ville blive meddelt. Hvilken interesse ville det være for Nexstim at holde sådan en positiv overraskelse hemmelig? Jeg fastholder min holdning om, at en betydelig Brainlab-handel først starter næste år og i høj grad følger den tidligere n...
9.12.2025, 16.51
af Kyhnykeisari
9
Det gik også til stregen i 2023. Forhåbentlig vil denne sæsonudsving udjævne sig lidt med Brainlab. Det er selvfølgelig svært at ændre hospitalernes måde at bruge penge på, men det er en meget spændende forretning på denne måde!
5.12.2025, 08.56
af Kyhnykeisari
9
Som barn var man nogle gange skuffet over spejdernes kalender, når der ikke kom chokolade ud af den. Denne kalender har indtil videre været endnu mere ubrugelig, men forhåbentlig begynder der senest i næste uge at komme mere interessante låger!
9.12.2025, 15.34
af Kyhnykeisari
8
Besøg forummet
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.